Skip to main navigation Skip to search Skip to main content

Incidence and outcomes among patients with HR+/HER2- metastatic breast cancer (mBC) with co-occurring ESR1 and PIK3CA mutations detected by ctDNA and treated with alpelisib: A retrospective review.

Research output: Contribution to journalArticlepeer-review

Original languageAmerican English
JournalDefault journal
StatePublished - Jun 2 2023

Cite this